The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
about
Implementing guidelines in primary care: can population impact measures help?ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryDiuretics for heart failureAldosterone antagonists for preventing the progression of chronic kidney diseaseDigitalis for treatment of heart failure in patients in sinus rhythmDiuretics for heart failureSpironolactone for hypertensionAldosterone antagonists for preventing the progression of chronic kidney diseaseDiuretics for heart failureDigitalis for treatment of heart failure in patients in sinus rhythmHow to assess the external validity and model validity of therapeutic trials: a conceptual approach to systematic review methodologyThe human steroid hydroxylases CYP1B1 and CYP11B2A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.Inhibitory effect of bufalin and cinobufagin on steroidogenesis via the activation of ERK in human adrenocortical cellsDrug discovery: lessons from evolutionDevices in the management of advanced, chronic heart failureAcute decompensated heart failure: contemporary medical managementShort term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutismAddition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathyMale gynecomastiaSpironolactone and risk of upper gastrointestinal events: population based case-control studyPopulation impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart diseaseDebate: Do all patients with heart failure require automatic implantable defibrillators for the prevention of sudden death?Assessing the impact of heart failure specialist services on patient populationsCytokines as new treatment targets in chronic heart failureAudit of therapeutic interventions in inpatient children using two scores: are they evidence-based in developing countries?Experience collecting interim data on mortality: an example from the RALES studyHeart failure guidelines and prescribing in primary care across EuropeMineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectivesHeart Failure: Diagnosis, Management and UtilizationRole of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial HypertensionImpact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsNovel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of CardiologyRecent advances in treatment of heart failure"Nihilism" of chronic heart failure therapy in children and why effective therapy is withheldLipids, blood pressure and kidney update 2015Review of the top 5 cardiology studies of 2013-14Emerging Novel Therapies for Heart FailureMineralocorticoid Receptors in the Pathophysiology of Vascular Inflammation and AtherosclerosisRenocardiac syndromes: physiopathology and treatment stratagems
P2860
Q21257249-5FC95447-E871-40CE-8DCD-CE3F21DF5CEDQ22241786-361DB9BB-2EB0-46E2-BA20-A8C884C88699Q24185944-099EF40B-6BBD-4347-88C6-FCA07651CC46Q24194979-1472BFC7-1F38-47DA-89C8-A3675284B9BEQ24194992-F2D42F9A-A9B2-4269-B49D-CDB9695E6555Q24203661-4F974EC6-BD42-40E1-9F4E-70D5C0E2DA64Q24236324-12B192D5-FF9B-4D02-B2CF-8BF4D0F4EC06Q24239909-E0407768-9A88-4DE5-AFCB-FE91496D4F9DQ24244710-2C0F425C-FDD3-4186-82BC-298BD04836A0Q24247158-6D12FE88-27A6-4633-8BCF-6108550D9F4DQ24289013-CC71C9DD-5686-47B2-9D8B-696F93F76865Q24321759-78AF0AB5-51F0-4403-A05D-6CB2FCA03501Q24604026-4FD236B8-9905-4D7E-A49F-783278264BFCQ24605993-F984F9FB-C823-4FF2-AFB3-47F704B40838Q24610693-76103F04-C9D4-4726-A9C7-95423796C1FEQ24630052-21451813-F3B7-445F-A413-8476156E714FQ24650932-DB407FCE-0E4E-48EF-988A-E3183535C845Q24653568-5405D553-F42F-4FF3-8940-535259162CAEQ24657470-D0B3D935-4566-4B8B-B0C2-B27C4098C334Q24658187-993F7389-8894-4565-83C2-A706B449A819Q24679905-714E19CF-69D3-4D20-8142-440A2211CF6AQ24682494-AE6A5D32-3FB6-41D2-ACBD-8FF22C338F12Q24792660-266DFFB9-E45E-45F2-9DFD-27B215DA779BQ24796348-CBA80A67-3409-4090-B53B-C78DB168935CQ24799394-E9BE9BFE-2284-4538-9B5B-37C360E2BB37Q24800327-17170C95-7685-4FEB-8F4D-AFBDEE20FF6CQ24804348-DC6E98B8-5796-4556-9F83-84F742E87C0EQ24816665-41AE9045-3E2D-4F3C-9BFA-13311154F9A8Q26741152-87F68D6E-24FC-4773-A14D-799E3ED3B8C4Q26745543-C1041BC1-5298-4EDE-8330-6053D53B85BEQ26747017-B2874549-5AC9-445A-BF1E-A0ACE5AD8B2EQ26764927-25E90E36-1D0D-4733-A457-280177F15C17Q26765793-116B0A67-C03F-4CF2-94BD-4A58D5944362Q26766223-7ED85A6A-C640-451B-9BBE-282B4FE3713AQ26768688-5DCF439F-1B30-4526-8FAF-75AB54ECFCA4Q26771550-A21DA0DB-474F-4B64-822F-B252268C8BE8Q26776254-0B22AD3E-04A7-4C9F-8F0A-69DC4BF65208Q26778111-81508A64-3B8F-4F88-AE9F-AA1CE9C2B8F6Q26781416-9B6C2037-6997-411B-816E-34382CD62B64Q26781936-F827187A-E14B-4A64-B130-69B59FC40B4A
P2860
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The effect of spironolactone o ...... Evaluation Study Investigators
@ast
The effect of spironolactone o ...... Evaluation Study Investigators
@en
The effect of spironolactone o ...... Evaluation Study Investigators
@nl
type
label
The effect of spironolactone o ...... Evaluation Study Investigators
@ast
The effect of spironolactone o ...... Evaluation Study Investigators
@en
The effect of spironolactone o ...... Evaluation Study Investigators
@nl
altLabel
The Effect of Spironolactone o ...... ents with Severe Heart Failure
@en
prefLabel
The effect of spironolactone o ...... Evaluation Study Investigators
@ast
The effect of spironolactone o ...... Evaluation Study Investigators
@en
The effect of spironolactone o ...... Evaluation Study Investigators
@nl
P2093
P3181
P1476
The effect of spironolactone o ...... Evaluation Study Investigators
@en
P2093
A Castaigne
J Palensky
P304
P3181
P356
10.1056/NEJM199909023411001
P407
P577
1999-09-02T00:00:00Z